Lipoprotein(a) - gaining clinical importance as a cardiovascular risk factor.  Current state of medical knowledge.

Maria Rybicka; Anna Seroka; Michał Obrębski; Justyna Chwiejczak; Aleksander Górny; Jan Kościan; Julita Młynarska; Karolina Szczerkowska; Anna Wójcik; Maria Mitkowska

doi:10.56782/pps.212

Data publikacji : 2024-08-14

Tom 22 Nr 3 (2024)

Lipoprotein(a) - gaining clinical importance as a cardiovascular risk factor. Current state of medical knowledge.

Maria Rybicka

Anna Seroka

Michał Obrębski

Justyna Chwiejczak

Aleksander Górny

Jan Kościan

Julita Młynarska

Karolina Szczerkowska

Anna Wójcik

Maria Mitkowska

DOI: https://doi.org/10.56782/pps.212

Abstrakt

Cardiovascular disease has been a major cause of human mortality worldwide for many decades. One of the risk factors for atherosclerosis that is gaining clinical importance is serum lipoprotein(a) (Lp(a)) concentration. The purpose of this publication is to present current knowledge regarding Lp(a) and currently available investigational drugs that reduce serum Lp(a). We also present current recommendations for interventions aimed at reducing the cardiovascular risk associated with high serum Lp(a) concentration. Lipoprotein(a) is a variant of low-density lipoprotein (LDL) containing an additional glycopeptide chain called apolipoprotein(a) (apo(a)) covalently linked to apolipoprotein B-100 (apoB-100). Increased serum Lp(a) is a well-established independent risk factor for atherosclerosis and aortic stenosis. Unlike LDL-cholesterol (LDL-C) concentration, serum Lp(a) does not decrease significantly as a result of recommended lifestyle changes nor as a result of the use of major hypocholesterolemic drug classes. Approximately 20% of people worldwide have high serum Lp(a). Current recommendation is to perform a screen for serum Lp(a) at least once in one’s lifetime in general population. Effective lowering of serum Lp(a) falls into the category of urgent unmet medical needs. In the absence of effective drugs to reduce serum Lp(a) in individuals with elevated Lp(a), intensified control of other cardiovascular risk factors and in extreme cases therapeutic apheresis are strongly recommended.

Podobne artykuły

Paulina Dąbrowska, Michał Żuber, Michał Dacka, Efficacy and Safety of Bempedoic Acid in Lipid Disorder Therapy: A Review of Clinical Trials , Prospects in Pharmaceutical Sciences: Tom 22 Nr 3 (2024)
Paulina Lis, Anna Lis, Wojciech Kaźmierski, Jakub Jurek, Mateusz Ziomek, Kinga Kocur, Anna Ziobro, Katarzyna Camlet, INCLISIRAN - A NEW SOLUTION FOR THE PREVENTION AND TREATMENT OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE , Prospects in Pharmaceutical Sciences: Tom 22 Nr 3 (2024)
Maciej Bara, Jakub Starownik, Jakub Szydło, Patryk Gryszkiewicz, Jakub Nieznański, Dapagliflozin - new solution in chronic kidney disease treatment , Prospects in Pharmaceutical Sciences: Tom 22 Nr 2 (2024)
Jakub Olszewski, Katarzyn Kozon, Andrzej Patyra, Flozins in heart failure – a new reimbursement indication , Prospects in Pharmaceutical Sciences: Tom 20 Nr 1 (2022)
Natalia Korytowska, Beata Pytlak, Mariusz Niemczyk, PRZEWLEKŁA CHOROBA NEREK ORAZ WYBRANE ASPEKTY MONITOROWANIA STANU BIORCÓW NERKI , Prospects in Pharmaceutical Sciences: Tom 18 Nr 4 (2020)
Adam Piasecki, Magdalena Sitnik, Jakub Olszewski, Maciej Bara, Katarzyna Herjan, Piotr Armański, The changing landscape of mineralocorticoid receptor antagonists – finerenone in cardiovascular and renal health , Prospects in Pharmaceutical Sciences: Tom 22 Nr 1 (2024)
Dominika Łacheta, Wioletta Olejarz, PROTECTIVE ROLE OF α-LIPOIC ACID IN ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES , Prospects in Pharmaceutical Sciences: Tom 17 Nr 8 (2019)
Tomasz Kordowski, Tomasz Tatara, Adam Fronczak, PRZEGLĄD AKTUALNYCH WYTYCZNYCH I BADAŃ ZASTOSOWANIA KWASU ACETYLOSALICYLOWEGO W PREWENCJI PIERWOTNEJ INCYDENTÓW SERCOWO-NACZYNIOWYCH , Prospects in Pharmaceutical Sciences: Tom 17 Nr 4 (2019)
Mateusz Sobczyk, Daria Żuraw, Paulina Oleksa, Kacper Jasiński, Mikołaj Porzak, Michał Dacka, SGLT2 inhibitors and their possible use in prevention and treatment of neurological diseases , Prospects in Pharmaceutical Sciences: Tom 22 Nr 1 (2024)
Zofia Suchocka, OTYŁOŚĆ - PRZYCZYNY I LECZENIE , Prospects in Pharmaceutical Sciences: Tom 1 Nr 1 (2003)

1 2 3 4 5 6 7 8 > >>

Możesz również Rozpocznij zaawansowane wyszukiwanie podobieństw dla tego artykułu.

Szczegóły

Bibliografia

Statystyki

Autorzy

Pobierz pliki

PDF (English)

Zasady cytowania

Rybicka, M., Anna Seroka, Michał Obrębski, Justyna Chwiejczak, Aleksander Górny, Jan Kościan, … Maria Mitkowska. (2024). Lipoprotein(a) - gaining clinical importance as a cardiovascular risk factor. Current state of medical knowledge. Prospects in Pharmaceutical Sciences, 22(3), 102–113. https://doi.org/10.56782/pps.212

Wskaźniki altmetryczne

Cited by / Share

Licencja

Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa 4.0 Międzynarodowe.

Bibliografia

Berg, K. A new serum type system in man—the L p system. Acta Pathol. Microbiol. Scand. 1963, 59(3), 369-382. DOI: 10.1111/j.1699-0463.1963.tb01808.x. DOI: https://doi.org/10.1111/j.1699-0463.1963.tb01808.x

Gaubatz, J. W.; Heideman, C.; Gotto, A. M.; Morrisett, J. D.; Dahlen, G. H. Human Plasma Lipoprotein [a]. Structural Properties. J. Biol. Chem. 1983, 258 (7), 4582–4589. DOI: https://doi.org/10.1016/S0021-9258(18)32663-2

Schmidt, K.; Noureen, A.; Kronenberg, F.; Utermann, G. Structure, Function, and Genetics of Lipoprotein (a). J. Lipid Res. 2016, 57 (8), 1339–1359. DOI: 10.1194/jlr.R067314. DOI: https://doi.org/10.1194/jlr.R067314

Albers, J. J.; Kennedy, H.; Marcovina, S. M. Evidence That Lp[a] Contains One Molecule of Apo[a] and One Molecule of apoB: Evaluation of Amino Acid Analysis Data. J. Lipid Res. 1996, 37 (1), 192–196. DOI: https://doi.org/10.1016/S0022-2275(20)37647-1

Eaton, D. L.; Fless, G. M.; Kohr, W. J.; McLean, J. W.; Xu, Q. T.; Miller, C. G.; et al. Partial Amino Acid Sequence of Apolipoprotein(a) Shows That It Is Homologous to Plasminogen. Proc. Natl. Acad. Sci. U.S.A. 1987, 84 (10), 3224–3228. DOI: 10.1073/pnas.84.10.3224. DOI: https://doi.org/10.1073/pnas.84.10.3224

Frank, S. L., Klisak, I., Sparkes, R. S., Mohandas, T., Tomlinson, J. E., McLean, J. W.; et al. The Apolipoprotein(a) Gene Resides on Human Chromosome 6q26-27, in Close Proximity to the Homologous Gene for Plasminogen. Hum. Genet. 1988, 79 (4). DOI: 10.1007/BF00282175. DOI: https://doi.org/10.1007/BF00282175

Cegla, J.; France, M.; Marcovina, S. M.; Neely, R. D. G. Lp(a): When and How to Measure It. Ann. Clin. Biochem. 2021, 58 (1), 16–21. DOI: 10.1177/0004563220968473. DOI: https://doi.org/10.1177/0004563220968473

Coassin, S.; Schönherr, S.; Weissensteiner, H.; et al. A Comprehensive Map of Single-Base Polymorphisms in the Hypervariable LPA Kringle IV Type 2 Copy Number Variation Region. J. Lipid Res. 2019, 60 (1), 186–199. DOI: 10.1194/jlr.M090381. DOI: https://doi.org/10.1194/jlr.M090381

Kronenberg, F.; Mora, S.; Stroes, E. S. G.; et al. Lipoprotein(a) in Atherosclerotic Cardiovascular Disease and Aortic Stenosis: A European Atherosclerosis Society Consensus Statement. Eur. Heart J. 2022, 43 (39), 3925–3946. DOI: 10.1093/eurheartj/ehac361. DOI: https://doi.org/10.1093/eurheartj/ehac361

Müller, N.; Schulte, D. M.; Türk, K.; Freitag-Wolf, S.; Hampe, J.; Zeuner, R.; et al. IL-6 Blockade by Monoclonal Antibodies Inhibits Apolipoprotein (a) Expression and Lipoprotein (a) Synthesis in Humans. J. Lipid Res. 2015, 56 (5), 1034–1042. DOI: 10.1194/jlr.P052209. DOI: https://doi.org/10.1194/jlr.P052209

Krempler, F.; Kostner, G.; Bolzano, K.; Sandhofer, F. Lipoprotein (a) Is Not a Metabolic Product of Other Lipoproteins Containing Apolipoprotein B. Biochim. Biophys. Acta. 1979, 575 (1), 63–70. DOI: 10.1016/0005-2760(79)90131-0. DOI: https://doi.org/10.1016/0005-2760(79)90131-0

Kraft, H. G.; Menzel, H. J.; Hoppichler, F.; Vogel, W.; Utermann, G. Changes of Genetic Apolipoprotein Phenotypes Caused by Liver Transplantation. Implications for Apolipoprotein Synthesis. J. Clin. Invest. 1989, 83 (1), 137–142. DOI: 10.1172/JCI113849. DOI: https://doi.org/10.1172/JCI113849

White, A. L.; Lanford, R. E. Cell Surface Assembly of Lipoprotein(a) in Primary Cultures of Baboon Hepatocytes. J. Biol. Chem. 1994, 269 (46), 28716–28723. DOI: https://doi.org/10.1016/S0021-9258(19)61964-2

Jawi, M. M.; Frohlich, J.; Chan, S. Y. Lipoprotein(a) the Insurgent: A New Insight into the Structure, Function, Metabolism, Pathogenicity, and Medications Affecting Lipoprotein(a) Molecule. J. Lipids. 2020, 2020, 1–26. DOI: 10.1155/2020/3491764. DOI: https://doi.org/10.1155/2020/3491764

Pasławska, A.; Tomasik, P. J. Lipoprotein(a)—60 Years Later—What Do We Know? Cells 2023, 12 (20), 2472. DOI: 10.3390/cells12202472. DOI: https://doi.org/10.3390/cells12202472

Nordestgaard, B.G.; Langsted, A. Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. J. Lipid Res. 2016, 57 (11), 1953-1975. DOI: 10.1194/jlr.R071233. DOI: https://doi.org/10.1194/jlr.R071233

Zioncheck, T.F.; Powell, L.M.; Rice, G.C.; Eaton, D.L.; Lawn, R.M. Interaction of recombinant apolipoprotein(a) and lipoprotein(a) with macrophages. J. Clin. Invest. 1991, 87 (3), 767-771. DOI: 10.1172/JCI115079. DOI: https://doi.org/10.1172/JCI115079

Haberland, M. E.; Fless, G. M.; Scanu, A. M.; Fogelman, A. M. Malondialdehyde Modification of Lipoprotein(a) Produces Avid Uptake by Human Monocyte-Macrophages. J. Biol. Chem. 1992, 267 (6), 4143–4151. DOI: https://doi.org/10.1016/S0021-9258(19)50640-8

Poon, M.; Zhang, X.; Dunsky, K. G.; Taubman, M. B.; Harpel, P. C. Apolipoprotein(a) Induces Monocyte Chemotactic Activity in Human Vascular Endothelial Cells. Circulation 1997, 96 (8), 2514–2519. DOI: 10.1161/01.CIR.96.8.2514. DOI: https://doi.org/10.1161/01.CIR.96.8.2514

Tomic Naglic, D.; Manojlovic, M.; Pejakovic, S.; Stepanovic, K.; Prodanovic Simeunovic, J. Lipoprotein(a): Role in Atherosclerosis and New Treatment Options. Biomol. Biomed. 2023, 23 (4), 575–583. DOI: 10.17305/bb.2023.8992. DOI: https://doi.org/10.17305/bb.2023.8992

Salonen, E. M.; Jauhiainen, M.; Zardi, L.; Vaheri, A.; Ehnholm, C. Lipoprotein(a) Binds to Fibronectin and Has Serine Proteinase Activity Capable of Cleaving It. EMBO J. 1989, 8 (13), 4035–4040. DOI: 10.1002/j.1460-2075.1989.tb08586.x. DOI: https://doi.org/10.1002/j.1460-2075.1989.tb08586.x

Schächinger, V.; Halle, M.; Minners, J.; Berg, A.; Zeiher, A. M. Lipoprotein(a) Selectively Impairs Receptor-Mediated Endothelial Vasodilator Function of the Human Coronary Circulation. J. Am. Coll. Cardiol. 1997, 30 (4), 927–934. DOI: 10.1016/S0735-1097(97)00237-4. DOI: https://doi.org/10.1016/S0735-1097(97)00237-4

Koschinsky, M. L.; Kronenberg, F. The Long Journey of Lipoprotein(a) from Cardiovascular Curiosity to Therapeutic Target. Atherosclerosis 2022, 349, 1–6. DOI: 10.1016/j.atherosclerosis.2022.04.017. DOI: https://doi.org/10.1016/j.atherosclerosis.2022.04.017

Takami, S.; Yamashita, S.; Kihara, S.; Ishigami, M.; Takemura, K.; Kume, N.; et al. Lipoprotein(a) Enhances the Expression of Intercellular Adhesion Molecule-1 in Cultured Human Umbilical Vein Endothelial Cells. Circulation 1998, 97 (8), 721–728. DOI: 10.1161/01.CIR.97.8.721. DOI: https://doi.org/10.1161/01.CIR.97.8.721

Stiekema, L. C. A.; Prange, K. H. M.; Hoogeveen, R. M.; Verweij, S. L.; Kroon, J.; Schnitzler, J. G.; et al. Potent Lipoprotein(a) Lowering Following Apolipoprotein(a) Antisense Treatment Reduces the pro-Inflammatory Activation of Circulating Monocytes in Patients with Elevated Lipoprotein(a). Eur. Heart J. 2020, 41 (24), 2262–2271. DOI: 10.1093/eurheartj/ehaa171. DOI: https://doi.org/10.1093/eurheartj/ehaa171

Van Der Valk, F. M.; Bekkering, S.; Kroon, J.; Yeang, C.; Van Den Bossche, J.; Van Buul, J. D.; et al. Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans. Circulation 2016, 134 (8), 611–624. DOI: 10.1161/CIRCULATIONAHA.116.020838 DOI: https://doi.org/10.1161/CIRCULATIONAHA.116.020838

Van Dijk, R. A.; Kolodgie, F.; Ravandi, A.; Leibundgut, G.; Hu, P. P.; Prasad, A.; et al. Differential Expression of Oxidation-Specific Epitopes and Apolipoprotein(a) in Progressing and Ruptured Human Coronary and Carotid Atherosclerotic Lesions. J. Lipid Res. 2012, 53 (12), 2773–2790. DOI: 10.1194/jlr.P030890. DOI: https://doi.org/10.1194/jlr.P030890

Enkhmaa, B.; Petersen, K. S.; Kris-Etherton, P. M.; Berglund, L. Diet and Lp(a): Does Dietary Change Modify Residual Cardiovascular Risk Conferred by Lp(a)? Nutrients 2020, 12 (7), 2024. DOI: 10.3390/nu12072024. DOI: https://doi.org/10.3390/nu12072024

Riches, K.; Porter, K. E. Lipoprotein(a): Cellular Effects and Molecular Mechanisms. Cholesterol 2012, 2012, 1–10. DOI: 10.1155/2012/923289. DOI: https://doi.org/10.1155/2012/923289

Patel, A. P.; Wang (汪敏先), M.; Pirruccello, J. P.; Ellinor, P. T.; Ng, K.; Kathiresan, S.; Khera, A. V. Lp(a) (Lipoprotein[a]) Concentrations and Incident Atherosclerotic Cardiovascular Disease: New Insights From a Large National Biobank. Arterioscler. Thromb. Vasc. Biol. 2021, 41 (1), 465–474. DOI: 10.1161/ATVBAHA.120.315291. DOI: https://doi.org/10.1161/ATVBAHA.120.315291

Kunutsor, S. K.; Mäkikallio, T. H.; Kauhanen, J.; Voutilainen, A.; Laukkanen, J. A. Lipoprotein(a) Is Not Associated with Venous Thromboembolism Risk. Scand. Cardiovasc. J. 2019, 53 (3), 125–132. DOI: 10.1080/14017431.2019.1612087 DOI: https://doi.org/10.1080/14017431.2019.1612087

Kamstrup, P. R.; Tybjærg¬-Hansen, A.; Nordestgaard, B. G. Genetic Evidence That Lipoprotein(a) Associates With Atherosclerotic Stenosis Rather Than Venous Thrombosis. ATVB 2012, 32 (7), 1732–1741. DOI: 10.1161/ATVBAHA.112.248765. DOI: https://doi.org/10.1161/ATVBAHA.112.248765

Arsenault, B. J.; Kamstrup, P. R. Lipoprotein(a) and Cardiovascular and Valvular Diseases: A Genetic Epidemiological Perspective. Atherosclerosis 2022, 349, 7-16. DOI: 10.1016/j.atherosclerosis.2022.04.015. DOI: https://doi.org/10.1016/j.atherosclerosis.2022.04.015

Nielsen, L. B.; Stender, S.; Kjeldsen, K.; Nordestgaard, B. G. Specific Accumulation of Lipoprotein(a) in Balloon-Injured Rabbit Aorta in Vivo. Circ. Res. 1996, 78 (4), 615–626. DOI: 10.1161/01.res.78.4.615. DOI: https://doi.org/10.1161/01.RES.78.4.615

Schnitzler, J. G.; Ali, L.; Groenen, A. G.; Kaiser, Y.; Kroon, J. Lipoprotein(a) as Orchestrator of Calcific Aortic Valve Stenosis. Biomolecules 2019, 9 (12), 760. DOI: 10.3390/biom9120760. DOI: https://doi.org/10.3390/biom9120760

Kronenberg, F. Lipoprotein(a) Measurement Issues: Are We Making a Mountain out of a Molehill? Atherosclerosis 2022, 349, 123–135. DOI: 10.1016/j.atherosclerosis.2022.04.008. DOI: https://doi.org/10.1016/j.atherosclerosis.2022.04.008

Heydari, M.; Rezayi, M.; Ruscica, M.; Jpamialahamdi, T.; Johnston, T. P.; Sahebkar, A. The Ins and Outs of Lipoprotein(a) Assay Methods. Arch. Med. Sci. Atheroscler. Dis. 2023, 8, e128–e139. DOI: 10.5114/amsad/176653. DOI: https://doi.org/10.5114/amsad/176653

McConnell, J. P.; Guadagno, P. A.; Dayspring, T. D.; Hoefner, D. M.; Thiselton, D. L.; Warnick, G. R.; et al. Lipoprotein(a) Mass: A Massively Misunderstood Metric. J. Clin. Lipidol. 2014, 8 (6), 550–553. DOI: 10.1016/j.jacl.2014.08.003. DOI: https://doi.org/10.1016/j.jacl.2014.08.003

Wilson, D. P.; Jacobson, T. A.; Jones, P. H.; Koschinsky, M. L.; McNeal, C. J.; Nordestgaard, B. G.; Orringer, C. E. Use of Lipoprotein(a) in Clinical Practice: A Biomarker Whose Time Has Come. A Scientific Statement from the National Lipid Association. J. Clin. Lipidol. 2019, 13 (3), 374–392. DOI: 10.1016/j.jacl.2019.04.010. DOI: https://doi.org/10.1016/j.jacl.2019.04.010

Vinci, P.; Di Girolamo, F. G.; Panizon, E.; Tosoni, L. M.; Cerrato, C.; Pellicori, F.; et al. Lipoprotein(a) as a Risk Factor for Cardiovascular Diseases: Pathophysiology and Treatment Perspectives. IJERPH 2023, 20 (18), 6721. DOI: 10.3390/ijerph2018672. DOI: https://doi.org/10.3390/ijerph20186721

Kronenberg, F.; Mora, S.; Stroes, E. S. G.; Ference, B. A.; Arsenault, B. J.; Berglund, L.; et al. Frequent Questions and Responses on the 2022 Lipoprotein(a) Consensus Statement of the European Atherosclerosis Society. Atherosclerosis 2023, 374, 107–120. DOI: 10.1016/j.atherosclerosis.2023.04.012. DOI: https://doi.org/10.1016/j.atherosclerosis.2023.04.012

Gudbjartsson, D. F.; Thorgeirsson, G.; Sulem, P.; Helgadottir, A.; Gylfason, A.; Saemundsdottir, J.; et al. Lipoprotein(a) Concentration and Risks of Cardiovascular Disease and Diabetes. J. Am. Coll. Cardiol. 2019, 74 (24), 2982–2994. DOI: 10.1016/j.jacc.2019.10.019. DOI: https://doi.org/10.1016/j.jacc.2019.10.019

Lp(a): A Toolkit for Health Care Professionals American Heart Association. Available online: https://aha-clinical-review.ascendeventmedia.com/books/lpa-a-toolkit-for-health-care-professionals (accessed on 16.03.2024).

Welsh, P.; Al Zabiby, A.; Byrne, H.; Benbow, H. R.; Itani, T.; Farries, G.; et al. Elevated Lipoprotein(a) Increases Risk of Subsequent Major Adverse Cardiovascular Events (MACE) and Coronary Revascularisation in Incident ASCVD Patients: A Cohort Study from the UK Biobank. Atherosclerosis 2024, 389, 117437. DOI: 10.1016/j.atherosclerosis.2023.117437. DOI: https://doi.org/10.1016/j.atherosclerosis.2023.117437

Kamstrup, P. R. Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction. JAMA 2009, 301 (22), 2331. DOI: 10.1001/jama.2009.801. DOI: https://doi.org/10.1001/jama.2009.801

Ziogos, E.; Vavuranakis, M. A.; Harb, T.; Foran, P. L.; Blaha, M. J.; Jones, S. R.; et al. Lipoprotein(a) Concentrations in Acute Myocardial Infarction Patients Are Not Indicative of Levels at Six Month Follow-Up. Eur. Heart J. Open 2023, 3 (2), oead035. DOI: 10.1093/ehjopen/oead035. DOI: https://doi.org/10.1093/ehjopen/oead035

Emerging Risk Factors Collaboration; Erqou, S.; Kaptoge, S.; Perry, P. L.; Di Angelantonio, E.; Thompson, A.; White, I. R.; et al. Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality. JAMA 2009, 302 (4), 412–423. DOI: 10.1001/jama.2009.1063. DOI: https://doi.org/10.1001/jama.2009.1063

Nave, A. H.; Lange, K. S.; Leonards, C. O.; Siegerink, B.; Doehner, W.; Landmesser, U.; et al. Lipoprotein (a) as a Risk Factor for Ischemic Stroke: A Meta-Analysis. Atherosclerosis 2015, 242 (2), 496–503. DOI: 10.1016/j.atherosclerosis.2015.08.021. DOI: https://doi.org/10.1016/j.atherosclerosis.2015.08.021

Erqou, S.; Thompson, A.; Di Angelantonio, E.; Saleheen, D.; Kaptoge, S.; Marcovina, S.; Danesh, J. Apolipoprotein(a) Isoforms and the Risk of Vascular Disease. J. Am. Coll. Cardiol. 2010, 55 (19), 2160–2167. DOI: 10.1016/j.jacc.2009.10.080. DOI: https://doi.org/10.1016/j.jacc.2009.10.080

Smolders, B.; Lemmens, R.; Thijs, V. Lipoprotein (a) and Stroke: A Meta-Analysis of Observational Studies. Stroke 2007, 38 (6), 1959–1966. DOI: 10.1161/STROKEAHA.106.480657. DOI: https://doi.org/10.1161/STROKEAHA.106.480657

Nave, A. H.; Von Eckardstein, A. Is Lipoprotein(a) a Risk Factor for Ischemic Stroke and Venous Thromboembolism? Clin. Res. Cardiol. Suppl. 2019, 14 (S1), 28–32. DOI: 10.1007/s11789-019-00101-8. DOI: https://doi.org/10.1007/s11789-019-00101-8

Thanassoulis, G.; Campbell, C. Y.; Owens, D. S.; Smith, J. G.; Smith, A. V.; Peloso, G. M.; et al. Genetic Associations with Valvular Calcification and Aortic Stenosis. N. Engl. J. Med. 2013, 368 (6), 503–512. DOI: 10.1056/NEJMoa1109034. DOI: https://doi.org/10.1056/NEJMoa1109034

Zheng, K. H.; Tsimikas, S.; Pawade, T.; et al. Lipoprotein(a) and Oxidized Phospholipids Promote Valve Calcification in Patients With Aortic Stenosis. J. Am. Coll. Cardiol. 2019, 73 (17), 2150–2162. DOI: 10.1016/j.jacc.2019.01.070. DOI: https://doi.org/10.1016/j.jacc.2019.01.070

Lipoprotein(a) in Clinical Practice. Available online: https://www.acc.org/Latest-in-Cardiology/Articles/2019/07/02/08/05/Lipoproteina-in-Clinical-Practice (accessed on 16.03.2024).

Tolbus, A.; Mortensen, M. B.; Nielsen, S. F.; Kamstrup, P. R.; Bojesen, S. E.; Nordestgaard, B. G. Kringle IV Type 2, Not Low Lipoprotein(a), as a Cause of Diabetes: A Novel Genetic Approach Using SNPs Associated Selectively with Lipoprotein(a) Concentrations or with Kringle IV Type 2 Repeats. Clin. Chem. 2017, 63 (12), 1866–1876. DOI: 10.1373/clinchem.2017.277103 DOI: https://doi.org/10.1373/clinchem.2017.277103

Mach, F.; Baigent, C.; Catapano, A. L.; Koskinas, K. C.; Casula, M.; Badimon, L.; et al. 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias: Lipid Modification to Reduce Cardiovascular Risk. Eur. Heart J. 2020, 41 (1), 111–188. DOI: 10.1093/eurheartj/ehz455. DOI: https://doi.org/10.1093/eurheartj/ehz455

Banach, M.; Burchardt, P.; Chlebus, K.; Dobrowolski, P.; Dudek, D.; Dyrbuś, K.; et al. PoLA/CFPiP/PCS/PSLD/PSD/PSH Guidelines on Diagnosis and Therapy of Lipid Disorders in Poland 2021. Arch. Med. Sci. 2021, 17 (6), 1447–1547. DOI: 10.5114/aoms/141941. DOI: https://doi.org/10.5114/aoms/141941

Sosnowska, B.; Surma, S.; Banach, M. Targeted Treatment against Lipoprotein (a): The Coming Breakthrough in Lipid Lowering Therapy. Pharmaceuticals 2022, 15 (12), 1573. DOI: 10.3390/ph15121573. DOI: https://doi.org/10.3390/ph15121573

Tsimikas, S.; Gordts, P. L. S. M.; Nora, C.; Yeang, C.; Witztum, J. L. Statin Therapy Increases Lipoprotein(a) Levels. Eur. Heart J. 2020, 41 (24), 2275–2284. DOI: 10.1093/eurheartj/ehz310. DOI: https://doi.org/10.1093/eurheartj/ehz310

Refusal of the marketing authorisation for Kynamro (mipomersen). Available online: https://www.ema.europa.eu/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-kynamro-mipomersen_en.pdf (accessed on 16.03.2024).

Withdrawal of Approval of 11 New Drug Applications. Available online: https://www.regulations.gov/document/FDA-2019-N-2040-0001 (accessed on: 16.03.2024).

Ruiz-Negrón, N.; Blumenthal, D. K. Drug Therapy for Dyslipidemias. In Goodman & Gilman’s: The Pharmacological Basis of Therapeutics, 14th Edition, Brunton, L. L., Knollmann, B. C., Eds.; McGraw-Hill Education: New York, NY, USA, 2023.

De Boer, L. M.; Oorthuys, A. O. J.; Wiegman, A.; Langendam, M. W.; Kroon, J.; Spijker, R.; et al. Statin Therapy and Lipoprotein(a) Levels: A Systematic Review and Meta-Analysis. Eur. J. Prev. Cardiol. 2022, 29 (5), 779–792. DOI: 10.1093/eurjpc/zwab171. DOI: https://doi.org/10.1093/eurjpc/zwab171

Wan, S.; Ding, Y.; Ji, X.; Meng, R. The Safety and Efficacy of Ezetimibe Plus Statins on ASVD and Related Diseases. Aging Dis. 2021, 12 (8), 1857. DOI: 10.14336/AD.2021.0412. DOI: https://doi.org/10.14336/AD.2021.0412

Sahebkar, A.; Simental-Mendía, L. E.; Pirro, M.; Banach, M.; Watts, G. F.; Sirtori, C.; et al. Impact of Ezetimibe on Plasma Lipoprotein(a) Concentrations as Monotherapy or in Combination with Statins: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Sci. Rep. 2018, 8 (1), 17887. DOI: 10.1038/s41598-018-36204-7. DOI: https://doi.org/10.1038/s41598-018-36204-7

on behalf of Lipid and Blood Pressure Meta-Analysis Collaboration (LBPMC) Group; Awad, K.; Mikhailidis, D. P.; Katsiki, N.; Muntner, P.; Banach, M. Effect of Ezetimibe Monotherapy on Plasma Lipoprotein(a) Concentrations in Patients with Primary Hypercholesterolemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Drugs 2018, 78 (4), 453–462. DOI: 10.1007/s40265-018-0870-1. DOI: https://doi.org/10.1007/s40265-018-0870-1

Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group; Sahebkar, A.; Simental-Mendía, L. E.; Watts, G. F.; Serban, M.-C.; Banach, M. Comparison of the Effects of Fibrates versus Statins on Plasma Lipoprotein(a) Concentrations: A Systematic Review and Meta-Analysis of Head-to-Head Randomized Controlled Trials. BMC Med. 2017, 15 (1), 22. DOI: 10.1186/s12916-017-0787-7. DOI: https://doi.org/10.1186/s12916-017-0787-7

Ko, H. S.; Kim, C. J.; Ryu, W. S. Effect of Fenofibrate on Lipoprotein(a) in Hypertriglyceridemic Patients: Impact of Change in Triglyceride Level and Liver Function. J. Cardiovasc. Pharmacol. 2005, 46 (4), 405–411. DOI: 10.1097/01.fjc.0000175875.48167.c7. DOI: https://doi.org/10.1097/01.fjc.0000175875.48167.c7

PCSK9 Inhibitors. Available online: https://www.ncbi.nlm.nih.gov/books/NBK448100/ (accessed on 15.03.2024).

Schwartz, G. G.; Ballantyne, C. M. Existing and Emerging Strategies to Lower Lipoprotein(a). Atherosclerosis 2022, 349, 110–122. DOI: 10.1016/j.atherosclerosis.2022.04.020. DOI: https://doi.org/10.1016/j.atherosclerosis.2022.04.020

O’Donoghue, M. L.; Fazio, S.; Giugliano, R. P.; Stroes, E. S. G.; Kanevsky, E.; Gouni-Berthold, I.; et al. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk: Insights From the FOURIER Trial. Circulation 2019, 139 (12), 1483–1492. DOI: 10.1161/CIRCULATIONAHA.118.037184. DOI: https://doi.org/10.1161/CIRCULATIONAHA.118.037184

Bittner, V. A.; Szarek, M.; Aylward, P. E.; Bhatt, D. L.; Diaz, R.; Edelberg, J. M.; et al. Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. J. Am. Coll. Cardiol. 2020, 75 (2), 133–144. DOI: 10.1016/j.jacc.2019.10.057. DOI: https://doi.org/10.1016/j.jacc.2019.10.057

Ray, K. K.; Vallejo-Vaz, A. J.; Ginsberg, H. N.; Davidson, M. H.; Louie, M. J.; Bujas-Bobanovic, M.; et al. Lipoprotein(a) Reductions from PCSK9 Inhibition and Major Adverse Cardiovascular Events: Pooled Analysis of Alirocumab Phase 3 Trials. Atherosclerosis 2019, 28, 194–202. DOI: 10.1016/j.atherosclerosis.2019.06.896. DOI: https://doi.org/10.1016/j.atherosclerosis.2019.06.896

Ray, K. K.; Wright, R. S.; Kallend, D.; Koenig, W.; Leiter, L. A.; Raal, F. J.; et al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N. Engl. J. Med. 2020, 382 (16), 1507–1519. DOI: 10.1056/NEJMoa1912387. DOI: https://doi.org/10.1056/NEJMoa1912387

A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease (ORION-4). Available online: https://classic.clinicaltrials.gov/ct2/show/NCT03705234 (accessed on 16.03.2024).

Ray, K. K.; Raal, F. J.; Kallend, D. G.; Jaros, M. J.; Koenig, W.; Leiter, L. A.; et al. Inclisiran and Cardiovascular Events: A Patient-Level Analysis of Phase III Trials. Eur. Heart J. 2023, 44 (2), 129–138. DOI: 10.1093/eurheartj/ehac594. DOI: https://doi.org/10.1093/eurheartj/ehac594

Hardy, J.; Niman, S.; Goldfaden, R. F.; Ashchi, M.; Bisharat, M.; Huston, J.; et al. A Review of the Clinical Pharmacology of Pelacarsen: A Lipoprotein(a)-Lowering Agent. Am. J. Cardiovasc. Drugs 2022, 22 (1), 47–54. DOI: 10.1007/s40256-021-00499-1. DOI: https://doi.org/10.1007/s40256-021-00499-1

Karwatowska Prokopczuk, E.; Lesogor, A.; Yan, J.-H.; Hurh, E.; Hoenlinger, A.; Margolskee, A.; et al. Efficacy and Safety of Pelacarsen in Lowering Lp(a) in Healthy Japanese Subjects. J. Clin. Lipidol. 2023, 17 (1), 181–188. DOI: 10.1016/j.jacl.2022.12.001. DOI: https://doi.org/10.1016/j.jacl.2022.12.001

Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD (Lp(a)HORIZON. Available online: https://www.clinicaltrials.gov/study/NCT04023552 (accessed on: 16.03.2024).

A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis. Available online: https://www.novartis.com/clinicaltrials/study/nct0564638 (accessed on: 30.05.2024)

O’Donoghue, M. L.; Rosenson, R. S.; Gencer, B.; López, J. A. G.; Lepor, N. E.; Baum, S. J.; et al. Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease. N. Engl. J. Med. 2022, 387 (20), 1855–1864. DOI: 10.1056/NEJMoa2211023. DOI: https://doi.org/10.1056/NEJMoa2211023

Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial. Available online: https://classic.clinicaltrials.gov/ct2/show/NCT05581303 (accessed on 16.03.2024).

Visseren, F. L. J.; Mach, F.; Smulders, Y. M.; Carballo, D.; Koskinas, K. C.; Bäck, M.; et al. Corrigendum to: 2021 ESC Guidelines on Cardiovascular Disease Prevention in Clinical Practice: Developed by the Task Force for Cardiovascular Disease Prevention in Clinical Practice with Representatives of the European Society of Cardiology and 12 Medical Societies With the Special Contribution of the European Association of Preventive Cardiology (EAPC). Eur. Heart J. 2022, 43 (42), 4468–4468. DOI: 10.1093/eurheartj/ehac458. DOI: https://doi.org/10.1093/eurheartj/ehac458

Weisman, S. M.; Angiolillo, D. J. Aspirin for Primary Prevention of Cardiovascular Disease: What We Now Know. J. Cardiol. Cardiovasc. Med. 2024, 9 (1), 006–013. DOI: 10.29328/journal.jccm.1001172. DOI: https://doi.org/10.29328/journal.jccm.1001172

Akaike, M.; Azuma, H.; Kagawa, A.; Matsumoto, K.; Hayashi, I.; Tamura, K.; et al. Effect of Aspirin Treatment on Serum Concentrations of Lipoprotein(a) in Patients with Atherosclerotic Diseases. Clin. Chem. 2002, 48 (9), 1454–1459. DOI: https://doi.org/10.1093/clinchem/48.9.1454

Bhatia, H. S.; Trainor, P.; Carlisle, S.; Tsai, M. Y.; Criqui, M. H.; DeFilippis, A.; Tsimikas, S. Aspirin and Cardiovascular Risk in Individuals With Elevated Lipoprotein(a): The Multi-Ethnic Study of Atherosclerosis. J. Am. Heart Assoc. 2024, 13 (3), e033562. DOI: 10.1161/JAHA.123.033562. DOI: https://doi.org/10.1161/JAHA.123.033562

Sukkari, M. H.; Al-Bast, B.; Al Tamimi, R.; Giesing, W.; Siddique, M. Is There a Benefit of Aspirin Therapy for Primary Prevention to Reduce the Risk of Atherosclerotic Cardiovascular Disease in Patients with Elevated Lipoprotein (a)-A Review of the Evidence. Am. J. Prev. Cardiol. 2023, 15, 100579. DOI: 10.1016/j.ajpc.2023.100579. DOI: https://doi.org/10.1016/j.ajpc.2023.100579

Tocilizumab. Available online: https://www.ncbi.nlm.nih.gov/books/NBK570644/ (accessed on: 31.05.2024)

Tsimikas, S.; Witztum, J. L. The Role of Oxidized Phospholipids in Mediating Lipoprotein(a) Atherogenicity. Curr. Opin. Lipidol. 2008, 19 (4), 369–377. DOI: 10.1097/MOL.0b013e328308b622. DOI: https://doi.org/10.1097/MOL.0b013e328308b622

Reyes-Soffer, G.; Westerterp, M. Beyond Lipoprotein(a) Plasma Measurements: Lipoprotein(a) and Inflammation. Pharmacol. Res. 2021, 169, 105689. DOI: 10.1016/j.phrs.2021.105689. DOI: https://doi.org/10.1016/j.phrs.2021.105689

Lipoprotein Apheresis. Available online: https://www.ncbi.nlm.nih.gov/books/NBK425700/ (accessed on 16.03.2024)

Connelly‐Smith, L.; Alquist, C. R.; Aqui, N. A.; Hofmann, J. C.; Klingel, R.; Onwuemene, O. A.; et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue. J. Clin. Apher. 2023, 38 (2), 77–278. DOI: 10.1002/jca.22043. DOI: https://doi.org/10.1002/jca.22043

Schettler, V. J. J.; Peter, C.; Zimmermann, T.; Julius, U.; Roeseler, E.; Schlieper, G.; et al. The German Lipoprotein Apheresis Registry—Summary of the Ninth Annual Report. Ther. Apher. Dial. 2022, 26 (S1), 81–88. DOI: 10.1111/1744-9987.13780. DOI: https://doi.org/10.1111/1744-9987.13780

Nugent, A. K.; Gray, J. V.; Gorby, L. K.; Moriarty, P. M. Lipoprotein Apheresis: First FDA Indicated Treatment for Elevated Lipoprotein(a). J. Clin. Cardiol. 2020, 1(1), 16–21. DOI: 10.33696/cardiology.1.002. DOI: https://doi.org/10.33696/cardiology.1.002

„Mało znana cząsteczka, która ma duży wpływ na powodowanie zawałów serca”. Dlaczego warto oznaczyć lipoproteinę a?. Available online: https://uck.pl/news/czasteczka-ktora-ma-duzy-wplyw-na-powodowanie-zawalow-serca-dlaczego-warto-oznaczyc-lipoproteine-a.html (accessed on: 16.02.2024)